01789nas a2200277   4500000000100000008004100001653001400042653002200056653001800078653001800096653002300114653003000137100001300167700001300180700001500193700001500208700001600223700001800239700001300257700001300270245007700283300001000360490000800370520111900378022001401497       2017                            d10aLiposomes10aNanobiotechnology10ananoemulsions10aNanoparticles10aNeglected Diseases10aSolid lipid nanoparticles1 aIslan GA1 aDurán M1 aCacicedo M1 aNakazato G1 aKobayashi R1 aMartinez DS T1 aCastro G1 aDurán N00aNanopharmaceuticals as a solution to neglected diseases: Is it possible?  a16-420 v1703 a<p>The study of neglected diseases has not received much attention, especially from public and private institutions over the last years, in terms of strong support for developing treatment for these diseases. Support in the form of substantial amounts of private and public investment is greatly needed in this area. Due to the lack of novel drugs for these diseases, nanobiotechnology has appeared as an important new breakthrough for the treatment of neglected diseases. Recently, very few reviews focusing on filiarasis, leishmaniasis, leprosy, malaria, onchocerciasis, schistosomiasis, trypanosomiasis, and tuberculosis, and dengue virus have been published. New developments in nanocarriers have made promising advances in the treatment of several kinds of diseases with less toxicity, high efficacy and improved bioavailability of drugs with extended release and fewer applications. This review deals with the current status of nanobiotechnology in the treatment of neglected diseases and highlights how it provides key tools for exploring new perspectives in the treatment of a wide range of diseases.</p>
  a1873-6254